| 产品详情 |
| Edit |   |
| Product Name | CPI-613 |
| Description | CPI-613 is a non-redox active lipoate derivative that acts as a selective inhibitor mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase. In vitro, CPI-613 dose-dependently and efficiently kills H460 human lung cancer cells and Saos-2 human sarcoma cells. In vitro, CPI-613 treatment potently disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity. CPI-613 treatment also leads to loss of mitochondrial membrane potential as assessed by JC-1 mitochondrial uptake. CPI-613 also induces apoptotic and non-apoptotic cell death in the cells of H460 human lung cancer and Saos-2 human sarcoma in vitro. MW: 388.59. Purity ≥98% by HPLC |
| Size | 10 mg |
| Concentration | n/a |
| Applications | n/a |
| Other Names | 6,8-Bis[(phenylmethyl)thio]octanoic acid |
| Gene, Accession, CAS # | CAS: 95809-78-2 |
| Catalog # | 9464-10 |
| Price | |
| Order / More Info | CPI-613 from BIOVISION, INC. |
| Product Specific References | n/a |
| 产品资料 |
|
|